...
首页> 外文期刊>Experimental and clinical endocrinology and diabetes: Official journal, German Society of Endocrinology [and] German Diabetes Association >Perioperative dexamethasone treatment in childhood craniopharyngioma - influence on short-term and long-term weight gain -.
【24h】

Perioperative dexamethasone treatment in childhood craniopharyngioma - influence on short-term and long-term weight gain -.

机译:儿童颅咽管瘤的围手术期地塞米松治疗-对短期和长期体重增加的影响-

获取原文
获取原文并翻译 | 示例

摘要

The substitution of dexamethasone during and after surgery of childhood craniopharyngioma is necessary in order to treat and/or prevent brain edema and adrenal insufficiency. Early post-operative weight gain is a predictor for severe obesity during long-term follow-up. In a retrospective analysis of 60 patients with childhood craniopharyngioma we inquired whether dose and duration of perioperative dexamethasone therapy (n = 68) had influence on short-term post-operative weight gain and long-term development of severe obesity. The median follow-up period was 4.2 years, ranging from 1 to 9 years. 24 patients (14 f/10 m) developed severe obesity (BMI > 3 SD). 28 patients (10 f/18 m) retained normal weight (BMI < 2 SD). Eight patients presented with a BMI between 2 and 3 SD at the final visit. Differences in terms of age at surgery or follow-up period were non-detectable between the analyzed groups of craniopharyngioma patients. Duration and cumulative dexamethasone doses (mg/m (2) BSA) for perioperative dexamethasone therapy were similar for severely obese patients (duration: 8.7 d; 4.5 - 17 d, cumulative dose: 74; 42 - 177 mg/m (2) BSA) and normal weight patients (duration: 10.0 d; 1 - 41 d; dose: 76; 9 - 390 mg/m (2) BSA). Whereas cumulative dexamethasone doses positively (p < 0.01; rho: 0.424) correlated with weight gain during the first year following surgery, long-term development of severe obesity was not influenced by dose and duration of perioperative dexamethasone treatment. Patients who developed severe obesity during follow-up had a higher (p < 0.001) BMI already at the time of diagnosis. We conclude that dose and duration of perioperative dexamethasone treatment had short-term effects on post-operative weight gain, but not on the development of long-term severe obesity. The results of our retrospective analysis are currently tested in a prospective surveillance study Kraniopharyngeom 2000 (www.kraniopharyngeom.com).
机译:为了治疗和/或预防脑水肿和肾上腺功能不全,在儿童颅咽管瘤手术期间和术后必须更换地塞米松。术后早期早期体重增加是长期随访期间严重肥胖的预测指标。在对60例儿童颅咽管瘤患者的回顾性分析中,我们询问围手术期地塞米松治疗的剂量和持续时间(n = 68)是否对短期术后体重增加和严重肥胖的长期发展有影响。中位随访期为4.2年,范围为1至9年。 24名患者(14 f / 10 m)发展为严重肥胖(BMI> 3 SD)。 28名患者(10 f / 18 m)保持正常体重(BMI <2 SD)。在最后一次就诊时,八名患者的BMI在2到3 SD之间。在分析的颅咽管瘤患者组之间,在手术或随访期间的年龄差异是无法检测到的。重度肥胖患者围手术期地塞米松治疗的持续时间和地塞米松累积剂量(mg / m(2)BSA)与持续肥胖患者相似(持续时间:8.7 d; 4.5-17 d,累积剂量:74; 42-177 mg / m(2)BSA )和体重正常的患者(持续时间:10.0 d; 1-41 d;剂量:76; 9-390 mg / m(2)BSA)。术后第一年,地塞米松的累积剂量与体重增加呈正相关(p <0.01; rho:0.424),而围手术期地塞米松治疗的剂量和持续时间则不影响严重肥胖的长期发展。随访期间出现严重肥胖的患者在诊断时已经具有较高的(p <0.001)BMI。我们得出结论,围手术期地塞米松治疗的剂量和持续时间对术后体重增加有短期影响,但对长期严重肥胖的发展没有影响。我们的回顾性分析结果目前已在前瞻性监视研究Kraniopharyngeom 2000(www.kraniopharyngeom.com)中进行了测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号